Glathion (Glation)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceGlutathioneGlutathione
Similar drugsTo uncover
  • Glathion
    powder w / m in / in 
    FARMLYUKS LLC     Russia
    • Dosage form: & nbsplyophilized powder for the preparation of a solution for intravenous and intramuscular administration
    Composition:

    Per 1 bottle:

    active substance: glutathione 0.3 g, 0.6 g, 1.2 g or 1.8 g.

    Description:

    The lyophilized powder is white or almost white in color.

    Pharmacotherapeutic group:Detoxifying agent
    ATX: & nbsp

    V.03.A.B   Antidotes

    Pharmacodynamics:

    Glutathione is a linear tripeptide with a sulfhydryl group, which includes L-glutamine, Lcysteine ​​and glycine. It plays an important function in the protection of body cells, being a strong antioxidant. In humans, a shortage of glutathione leads to many diseases, such as Parkinson's disease, type I tyrosinemia, alcohol poisoning, and others. Experiments in vivo and in vitro have shown that a shortage of glutathione can lead to damage to mitochondria and cell death caused by an increase in the number of toxic oxygen species leading to an increase in the number of free radicals.

    Glutathione is able to prevent cell damage by combining with toxic substances and / or their metabolites. The neutralization of xenobiotics with glutathione can be carried out in three different ways: by conjugation of the substrate with glutathione,as a result of nucleophilic substitution and as a result of the reduction of organic peroxides to alcohols.

    The system of neutralization with the participation of glutathione plays a unique role in the formation of resistance of the organism to the most diverse influences and is the most important protective mechanism of the cell. During the biotransformation of some xenobiotics with the participation of glutathione, thioethers are formed, which are then converted to mercaptans, among which toxic products are found. But glutathione conjugates with most xenobiotics are less reactive and more hydrophilic than the starting materials, and therefore less toxic and easier to remove from the body.

    Glutathione binds a huge number of lipophilic compounds (physical neutralization), preventing their introduction into the lipid layer of membranes and disruption of cell functions.

    In this way, glutathione improves the stability of the cell membrane, protects the membrane of the liver cells, increases the activity of enzymes and the liver and promotes detoxification and restorative activity of the liver by the destruction of free radicals.

    Pharmacokinetics:

    15 minutes after intravenous infusion of 2 g of glutathione, the average concentration of glutathione in the blood is 444 mmol / L (average physiological concentration of glutathione in the blood is 6.9 mmol / L). The volume of distribution is 15 liters. The elimination half-life is 10 minutes. Clearance - 850 ml / min. Excreted urine in unchanged form or as cysteine ​​90 minutes after infusion.

    Indications:

    - In the complex therapy of liver diseases, such as acute and chronic hepatitis of various etiologies (viral, alcoholic, toxic), alcoholic cirrhosis, hepatic steatosis, liver fibrosis;

    - liver damage caused by the use of anti-tuberculosis, anticonvulsant drugs, herbal preparations, antibiotics, lipid-lowering drugs, NSAIDs, hormonal, psychotropic drugs and drugs for the treatment of gout;

    - to reduce and prevent hepatotoxicity, nephrotoxicity and neuropathy in the use of chemotherapeutic drugs (cisplatin, cyclophosphamide, doxorubicin and bleomycin).

    Contraindications:

    Individual intolerance to the components of the drug, children's age.

    Carefully:

    Elderly age (the drug should be administered in low doses with careful monitoring of the condition).

    Pregnancy and lactation:

    Contraindicated use during pregnancy and lactation. If it is necessary to use the drug during lactation, breastfeeding should be stopped.

    Dosing and Administration:

    With intravenous administration the contents of the vial are dissolved in 250-500 ml of a 0.9% solution of sodium chloride. The drug solution is used immediately after preparation, re-use of the remaining solution is not allowed.

    In severe forms of hepatitis of different etiology - 1,2-2,4 g intravenously per day for 30 days in the form of infusions.

    With alcoholic hepatitis - 1.8 g intravenously daily for 14-30 days in the form of infusions.

    With alcoholic cirrhosis 1.2 g intravenously daily for 30 days in the form of infusions.

    With hepatic steatosis - 1.8 g intravenously daily for 30 days in the form of infusions.

    With liver damage caused by taking medications - 1,2-1,8 g intravenously per day for 14-30 days in the form of infusions.

    To reduce the toxicity of cisplatin, cyclophosphamide, doxorubicin and bleomycin the initial dose is 1.5 g diluted in 100 ml of a 0.9% solution of sodium chloride or 5% glucose solution for a 15-minute intravenous infusion, from the second to the fifth day - 600 mg per day intramuscularly. In appointing cisplatin, the Glatiion dose should not exceed 35 mg of glutathione per 1 mg of cisplatin to prevent its effect on chemotherapy (with the exception of the corresponding doctor's recommendations).

    Intravenous infusion should be slow.

    With intramuscular injection: 0.3 g diluted in 3 ml of 0.9% sodium chloride solution, 0.6 g diluted in 4 ml of 0.9% sodium chloride solution. The drug must be completely dissolved in the solvent. The solution should be clear and colorless.

    1.2 g and 1.8 g intramuscularly are not administered.

    Side effects:

    There may be allergic reactions, lowering blood pressure, reducing or increasing the heart rate, heart palpitations, dyspeptic disorders that occur after discontinuation of the drug.

    Overdose:

    There were no cases of overdose. If an overdose occurs, symptomatic therapy should be used.

    Interaction:

    Avoid the simultaneous use with sodium menadione bisulphite, cyanocobalamin, calcium pantothenate, sulfonamide preparations and tetracyclines.

    Special instructions:

    When allergy symptoms appear, discontinue use of the drug.

    Effect on the ability to drive transp. cf. and fur:

    In view of the possible manifestations of side effects of the drug, caution should be exercised in persons administering vehicles and servicing mechanisms.

    Form release / dosage:

    Lyophilized powder for the preparation of a solution for intravenous and intramuscular administration, 0.3 g, 0.6 g, 1.2 g and 1.8 g.

    Packaging:

    By 0,3 g or 0,6 g of active substance in a bottle of colorless glass with a capacity of 5 ml, sealed with a plug of butyl rubber, crimped aluminum and a cap type flip-off. By 1,2, 3, 4, 5, 6, 7, 8, 9 or 10 vials are placed in a plastic pallet, then in a cardboard box together with instructions for medical use.

    According to 1.2 g of active substance in a bottle of colorless glass with a capacity of 10 ml, corked with a butyl rubber stopper, crimped aluminum and a lid of the type flip-off. By 1,2, 3, 4, 5, 6, 7, 8, 9 or 10 vials are placed in a plastic pallet, then in a cardboard box together with instructions for medical use.

    By 1.8 g of active substance into a bottle of colorless glass with a capacity of 15 ml, sealed with a plug of butyl rubber, crimped with aluminum rolling and a lid of type flip-off. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 vials are placed in a plastic pallet, then in a cardboard box together with instructions for medical use.

    Storage conditions:

    In a dry, dark place at a temperature of 15 to 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    2 years.

    Do not use after the expiration date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-001337
    Date of registration:08.12.2011
    Expiration Date:08.12.2016
    Date of cancellation:2016-12-08
    The owner of the registration certificate:FARMLYUKS LLC FARMLYUKS LLC Russia
    Manufacturer: & nbsp
    Representation: & nbspFARMLYUKS LLC FARMLYUKS LLC Russia
    Information update date: & nbsp25.04.2017
    Illustrated instructions
      Instructions
      Up